ImmunoGen

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Type
Public
HQ
Waltham, US
Founded
1981
Employees
317 (est)+6%
ImmunoGen was founded in 1981 and is headquartered in Waltham, US

Key People at ImmunoGen

Daniel M. Junius

Daniel M. Junius

President & CEO
Stephen C. McCluski

Stephen C. McCluski

Chairman
Gregory D. Perry

Gregory D. Perry

EVP & CFO

ImmunoGen Locations

Waltham, US
Brentwood, US
Norwood, US

ImmunoGen Metrics

ImmunoGen Summary

Market capitalization

$212 M

Closing share price

$2.48
ImmunoGen's current market capitalization is $212 M.

ImmunoGen Financials

ImmunoGen's revenue is $60 M in FY, 2016 which is 29.86% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$59.9 M$85.5 M$60 M

Operating income

$-71.5 M$-54.5 M$-125 M

Operating expense total

$131 M$140 M$185 M

Net Income

$-71.4 M$-60.7 M$-145 M

Operating cash flow

$-52.7 M$136 M$-33.1 M

    ImmunoGen Market Value History

    ImmunoGen Online Presence

    ImmunoGen Company Life

    You may also be interested in